| Objective To assess the efficacy of Kidney-tonifying Chinese Patent Medicine on bone turnover makers in the treatment of postmenopausal osteoporosis (PMOP). Methods Databases including PubMed, Cochrane Library, CNKI, WanFang Data and CBM were searched to collect randomized controlled trials and controlled clinical trial related to Kidney-tonifying Chinese Patent Medicine versus other methods in the treatment of PMOP. Systematic review was conducted based on the declaration of PRISMA, and meta-analysis was completed using RevMan 5.3 and R3.4.3. Results A total of 15 studies were included in the analysis, including 1388 patients. Qualitative analysis showed that compared with the control group, the kidney-tonifying Chinese patent medicine group had no significant effect on P1NP [WMD=-4.10, 95% CI [-9.18, 0.98 ], P=0.11], and could down-regulate β-CTX [WMD =-66.85, 95% CI(-125.83, -7.87), P=0.03], up-regulate BALP [WMD=10.12, 95% CI(7.35, 12.90), P<0.01], and up-regulate Osteocalcin [WMD=2.70, 95% CI (0.46, 4.94), P=0.02]. In the subgroup analysis of osteocalcin, the kidney-tonifying Chinese patent medicine in the non-elevated subgroup could down-regulate osteocalcin [WMD=-2.76, 95% CI(-3.99, -1.53), P<0.01], while in the ascending subgroup could up-regulate osteocalcin [WMD=4.22, 95% CI (1.80, 6.63), P=0.0006]. Conclusion Kidney-tonifying Chinese Patent Medicine can inhibit bone resorption level in PMOP, but its effect on bone formation is still uncertain. The influence of kidney-tonifying Chinese patent medicines on bone formation may be related to the specific drugs used. Epimedium and acanthopanax senticosus can promote bone formation, but the influence of other drugs is not obvious. However, due to the low quality of the literature included, more rigorous research is still needed to confirm the findings |